Twitter was awash with thousands of tweets (click link to left to read them) the past few days regarding the FDA's hearing today and yesterday about regulation of pharmaceutical marketing on the internet and using social media. Above is the word cloud for the tweetstream on the topic (minus all the references to fdasm, fda, RT, bit.ly, http, etc).
If you want to dive deeper, check out the links on tr.im/hitlinks and on fdasm.com. A list of links to many of the presentations are available here. Public comments to the FDA are being accepted through Feb 28, so go to one of the above links to find the public comments page if you have something to say about this area. The controversies involve things like providing fair balance in 140 characters, making it easier to find plain English info on adverse effects, and whether the FDA rules about drug companies hunting down every mention of adverse effects should be revised based on the preponderance of user-generated content out there.
No comments:
Post a Comment
In contributing to this blog the commenter grants permission to us to reuse material in any forthcoming book projects without payment We shall attempt to contact participants directly where portions to be used exceed more than a few sentences, but in the event contributions are anonymous participation shall be deemed to indicate consent. Names of commenters, including 'handles,' will not be used without specific consent.
Polite discourse is encouraged; civility is required or comments will be deleted